Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Redhill Rises Most in a Month as FDA Approves Drug Trial

Feb. 12 (Bloomberg) -- Redhill Biopharma Ltd. surged the most in almost one month after the Israeli biopharmaceutical company said it received U.S. Food and Drug Administration approval for a clinical trial of its RHB-102 drug.

The shares jumped 2.8 percent, the most since Jan. 19, to 2.201 shekels at the 5 p.m. close in Tel Aviv, giving the company a market value of 113 million shekels ($30 million).

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at

To contact the editor responsible for this story: Claudia Maedler at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.